{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.01","upperLimit":"28.81","value":"23.46"},{"groupId":"OG001","lowerLimit":"21.49","upperLimit":"27.63","value":"24.08"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"285"}],"units":"Participants"}],"description":"OS was defined as the time from date of randomization to the date of death from any cause. Final OS was conducted when 388 deaths occurred.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)","id":"OG000","title":"Everolimus + Vinorelbine + Trastuzumab"},{"description":"Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)","id":"OG001","title":"Placebo + Vinorelbine + Trastuzumab"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients.","reportingStatus":"POSTED","timeFrame":"Every 3 months until death up to 41 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}